about
Vaccines: from empirical development to rational designToll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responsesAlphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunizationSystems biology applied to vaccine and immunotherapy developmentThe adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primatesVirus-like particles as universal influenza vaccinesInnateDB: facilitating systems-level analyses of the mammalian innate immune response.Immunogenomics and systems biology of vaccines.Design and synthesis of potent Quillaja saponin vaccine adjuvantsChemical synthesis and proinflammatory responses of monophosphoryl lipid A adjuvant candidates.Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategyUnraveling molecular signatures of immunostimulatory adjuvants in the female genital tract through systems biologyConjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitisHuman Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-aminesTLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection.Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probesThe microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.Division of labor, plasticity, and crosstalk between dendritic cell subsets.Rapid loss of dendritic cell and monocyte responses to TLR ligands following venipunctureUptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome.Potent adjuvant activity of cationic liposome-DNA complexes for genital herpes vaccinesIn vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli.MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantDendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.Ebola virus-like particles stimulate type I interferons and proinflammatory cytokine expression through the toll-like receptor and interferon signaling pathways.Validation of a high-throughput methodology to assess the effects of biomaterials on dendritic cell phenotype.Heat-labile enterotoxins as adjuvants or anti-inflammatory agents.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Use of defined TLR ligands as adjuvants within human vaccines.Confronting the barriers to develop novel vaccines against brucellosis.Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems.Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.Targeting human dendritic cells in situ to improve vaccines.Adjuvants and delivery systems for antifungal vaccines: current state and future developments.A combined fermentative-chemical approach for the scalable production of pure E. coli monophosphoryl lipid A.Adverse events following immunization with vaccines containing adjuvants.Scientific Opinion on the assessment of allergenicity of GM plants and microorganisms and derived food and feedA Semisynthetic Approach to New Immunoadjuvant Candidates: Site-Selective Chemical Manipulation of Escherichia coli Monophosphoryl Lipid A.
P2860
Q21089599-78742507-740B-4E51-82BC-9A4B0A28879FQ24624348-8ED79673-43BE-4C2E-9C20-371D6B1A508EQ24634730-DC9CF80E-4A10-4808-B935-9A2360B4130CQ26830374-7A3FBCD3-8CE1-4418-A664-5198B603B526Q28729899-99DED890-6FC0-44FF-8967-78DAC715F7F2Q30421558-6FF23531-186A-4558-AA59-D0540F54A053Q30484002-AEEF4D02-6875-4765-B067-084AC6683381Q33350387-52B77DED-7240-4E90-96B5-D694A34A1FCCQ33645835-770D1675-07D3-4572-B6BF-C77CFEB2D57FQ33714195-8E2AB470-3C7A-44C7-92D7-2252200DD2ADQ33749309-A5A0F5C0-2270-4D51-ADE2-4AB363960298Q33930469-930C4EF1-9EAA-4256-80EE-103E424D95DAQ34053031-A8AB392D-380E-447F-8B7A-4DC2C2549FE8Q34164851-3336EB25-9335-4CEC-9888-A787100D1F70Q34807008-52D31378-3116-4457-B8BF-4A5D324F81E4Q36216866-CBA3EB3E-B419-47FE-8E22-EDA7688C4844Q36497412-09C6F4A9-DFD0-4B31-853F-A4247964F01CQ37033013-A804CE8E-7762-4FB2-BC7E-C61248AD9A48Q37036594-EAB0AAF1-C302-4197-A4DB-A2E900E0D0D5Q37070610-ED5A3D82-46E8-4DC4-ABF0-190F725B3C8AQ37190935-2AD7D6BF-D964-475D-AE49-6E45604B4B31Q37238638-03523B47-AB72-4EC9-AA33-7FF42C9B09D3Q37243896-0D477356-8DD0-4BCA-B2ED-399DAC4D305AQ37273249-6FE4D63E-F3BF-44A7-B357-953D8AA444C9Q37584926-76C9CD97-6D60-4FA4-86F0-851171EB1E5EQ37675408-2E9C92B3-42D1-4861-AD8D-0B7436703AB5Q37749719-04202A6A-FCD3-4950-B997-A2E136750740Q37785949-3596576D-3A78-4DA9-8F25-10268FF85BE8Q37825528-3D1EC200-8F7E-4038-91AF-9ED16E623ABCQ37932521-97848DAB-599D-4F85-B0FD-EE88276001E6Q37965724-DE3C1881-6770-442D-B8C1-199F9BEDA956Q38058640-422109F4-61A8-4469-9B1C-799387EBDEFAQ38235001-0F6B9B13-BDFB-40A7-85FA-D5A592872484Q38264288-CA12E964-B6D8-439D-BFA2-C9B941B4E9A0Q38983228-1D47D3A6-16B4-4BA2-B81E-50E0804DD1D4Q40251518-3EC53733-404F-4730-9D0B-371949726514Q47148622-910B0768-1E9E-49D7-949E-19B1D8C5E6AAQ48196685-6B3E4FC1-C532-4CAF-99CE-F7CEE9A9A655
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The science of adjuvants.
@en
type
label
The science of adjuvants.
@en
prefLabel
The science of adjuvants.
@en
P2093
P2860
P356
P1476
The science of adjuvants.
@en
P2093
Bali Pulendran
Marcin Kwissa
Sudhir Pai Kasturi
P2860
P304
P356
10.1586/14760584.6.5.673
P577
2007-10-01T00:00:00Z